"Deutsche Bank-North America analyst Mark Schoenebaum reaffirmed a``Hold""rating and cut his price target to $65 from $73 and expects the FDA delay to affect Myozyme sales."
"Jefferies & Co. analyst Eun K. Yang took a more positive outlook on the stock, reaffirming a``Buy""rating with a $88 price target."